aTyr Pharma (NASDAQ: LIFE) reported Q2 EPS of ($0.65), $0.06 better than the analyst estimate of ($0.71).

Financial Guidance

As of June 30, 2016, we had $96.6 million in cash, cash equivalents and investments and 23.7 million shares of common stock outstanding.

We currently expect that our cash, cash equivalents and investments will be sufficient to fund our anticipated operations into 2018.

For earnings history and earnings-related data on aTyr Pharma (LIFE) click here.